6 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival ... #EBM #Honc #Osimertinib ... #NSCLC #Survival ... #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
Progression-free Survival ... #EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Major Clinical Trials and Evidence Summary for Transfusion Thresholds in Critical Care

TRICC - NEJM 1999 -
Care TRICC - NEJM ... 1999 - ICU FOCUS ... - NEJM 2011 - Hip ... UGIB TRISS - NEJM ... critically ill, septic, surgical
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
Non–Small-Cell Lung Cancer (NSCLC ... classification of NSCLC ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma - Recurrence-free Survival in the
Recurrence-free Survival ... Population #EBM #Honc ... Ipilimumab #Melanoma #NEJM